# DIrect Oral Anticoagulation and Bioprothesis Aortic Valve

> **NCT05687448** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 1500 (estimated)

## Conditions studied

- Aortic Valve Disease

## Interventions

- **DRUG:** Apixaban 5 MG Oral Tablet
- **DRUG:** Aspirin 75 to 100mg once a day

## Key facts

- **NCT ID:** NCT05687448
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2025-09
- **Final completion:** 2029-03
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05687448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05687448, "DIrect Oral Anticoagulation and Bioprothesis Aortic Valve". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05687448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*